Literature DB >> 16515909

Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats.

Akira Marui1, Keiichi Hirose, Takayuki Maruyama, Yoshio Arai, Yuhong Huang, Kazuhiko Doi, Tadashi Ikeda, Masashi Komeda.   

Abstract

OBJECTIVE: Sternal wound complications are devastating events occurring in coronary artery bypass surgery, particularly in patients with diabetes. Prostaglandin E2 receptors have 4 subtypes, and the activation of the EP4 receptor induces bone regeneration. The present study investigated the utility of a prostaglandin E2 EP4 receptor-selective agonist in sternal healing after median sternotomy with the removal of the bilateral internal thoracic arteries in diabetic rats.
METHODS: Diabetic Wistar rats with blood glucose levels of greater than 400 mg/dL were established by means of a single intraperitoneal injection of streptozotocin. After median sternotomy and bilateral internal thoracic artery removal in 16 diabetic rats, 8 rats were administered the EP4 agonist (300 microg) on the posterior table of the sternum (EP4 group), whereas 8 did not receive any treatment (control group). Sternal healing and incidence of sternal wound complications were evaluated 4 weeks after the operation.
RESULTS: Sternal wound complications developed in 5 rats in the control group but in only 1 rat in the EP4 group (P < .01). Histologic examination revealed an almost completely healed sternum filled with regenerated bone tissue only in the EP4 group. Both bone mineral content and bone mineral density, as assessed with dual-energy x-ray absorptiometry, were higher in the EP4 group than in the control group (71.7 +/- 12.1 vs 48.9 +/- 11.7 mg for bone mineral content [P < .01] and 66.8 +/- 14.6 vs 47.9 +/- 6.3 mg/mm2 for bone mineral density [P < .05]).
CONCLUSIONS: The prostaglandin E2 EP4 agonist accelerated the sternal healing and decreased the incidence of sternal wound complications in the diabetic ischemic sternum. This method might help in decreasing sternal necrosis in high-risk patients or permit wider application of bilateral internal thoracic arteries in coronary artery bypass surgery, even in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515909     DOI: 10.1016/j.jtcvs.2005.10.026

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Prostaglandin E(2) receptors in bone formation.

Authors:  M Li; D D Thompson; V M Paralkar
Journal:  Int Orthop       Date:  2007-06-26       Impact factor: 3.075

2.  Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice.

Authors:  Kiminori Yukata; Chao Xie; Tian-Fang Li; Matthew L Brown; Tsukasa Kanchiku; Xinping Zhang; Hani A Awad; Edward M Schwarz; Christopher A Beck; Jennifer H Jonason; Regis J O'Keefe
Journal:  Bone       Date:  2018-02-03       Impact factor: 4.398

3.  Staphylococcus aureus recognition by hematopoietic stem and progenitor cells via TLR2/MyD88/PGE2 stimulates granulopoiesis in wounds.

Authors:  Jennifer L Granick; Patrick C Falahee; Delsheen Dahmubed; Dori L Borjesson; Lloyd S Miller; Scott I Simon
Journal:  Blood       Date:  2013-07-18       Impact factor: 22.113

Review 4.  A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart.

Authors:  Satsuki Fukushima; Shigeru Miyagawa; Yoshiki Sakai; Yoshiki Sawa
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

5.  Improved homology modeling of the human & rat EP4 prostanoid receptors.

Authors:  Melissa C Holt; Chi S Ho; M Inés Morano; Stephen D Barrett; Adam J Stein
Journal:  BMC Mol Cell Biol       Date:  2019-08-27

Review 6.  Role of prostaglandin E2 in tissue repair and regeneration.

Authors:  Hui Cheng; Haoyan Huang; Zhikun Guo; Ying Chang; Zongjin Li
Journal:  Theranostics       Date:  2021-08-13       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.